Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATM | Q13315 | 1/20 | 0.51 |
| ▸ | CTRB1 | P17538 | 2/20 | 0.48 |
| ▸ | CTSK | P43235 | 3/20 | 0.46 |
| ▸ | CTSL | P07711 | 2/20 | 0.46 |
| ▸ | CTSS | P25774 | 2/20 | 0.46 |
| ▸ | ELANE | P08246 | 1/20 | 0.46 |
| ▸ | CTSB | P07858 | 1/20 | 0.46 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29401219 | 0.86 | ALDH1A1 (0.54) | ATMCTSKCTSLCTSSCTSB | |
| SCHEMBL254638 | 0.85 | ITGB3 (0.53) | CTSKCTSLCTSSCTSB | |
| SCHEMBL24795018 | 0.85 | ITGB3 (0.53) | CTSKCTSLCTSSCTSB | |
| SCHEMBL4178755 | 0.85 | ITGB3 (0.53) | CTSKCTSLCTSSCTSB | |
| SCHEMBL29576042 | 0.83 | CTSK (0.50) | CTSKCTSLCTSSCTSB | |
| SCHEMBL27506310 | 0.83 | CTSL (0.51) | CTRB1CTSKCTSLCTSSCTSB | |
| SCHEMBL6218674 | 0.83 | CTRB1 (0.46) | ATMCTRB1CTSKCTSLCTSS | |
| SCHEMBL8359365 | 0.83 | CTRB1 (0.46) | ATMCTRB1CTSKCTSLCTSS | |
| SCHEMBL12409587 | 0.83 | CTSL (0.47) | ATMCTRB1CTSKCTSLCTSS | |
| SCHEMBL10684888 | 0.82 | CTSK (0.49) | CTSKCTSBALDH1A1ALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130023463-A1 | HIV PROTEASE INHIBITING COMPOUNDS | ABBOTT LABORATORIES (US) | 2013-01-24 | — | — | US | disclosed |
| US-8193227-B2 | HIV protease inhibiting compounds | ABBOTT LABORATORIES (US) | 2012-06-05 | — | — | US | disclosed |
| US-20110003827-A1 | HIV protease inhibiting compounds | ABBVIE INC. | 2011-01-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110003827-A1 | HIV protease inhibiting compounds | SERPINB1, HPN, DNPEP | ATM 4055/4885CTRB1 168/4885CTSK 76/4885 |
| US-20130023463-A1 | HIV PROTEASE INHIBITING COMPOUNDS | SERPINB1, HPN, DNPEP | ATM 4055/4885CTRB1 168/4885CTSK 76/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.